Premium
Serum vascular endothelial growth factor B is elevated in women with polycystic ovary syndrome and can be decreased with metformin treatment
Author(s) -
Cheng Feifei,
Zhao Lu,
Wu Yuanyuan,
Huang Tiantian,
Yang Gangyi,
Zhang Zhanyu,
Wu Yijia,
Jia Fang,
Wu Jinlin,
Chen Chen,
Liu Dongfang
Publication year - 2016
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/cen.12950
Subject(s) - polycystic ovary , metformin , medicine , endocrinology , insulin resistance , ovary , body mass index , overweight , vascular endothelial growth factor , insulin , vegf receptors
Summary Objective To determine serum vascular endothelial growth factor B (VEGF‐B) levels in polycystic ovary syndrome, their association with insulin resistance and β‐cell dysfunction, and the effect of metformin on serum VEGF‐B levels. Design A cross‐sectional, interventional study. Patients We recruited 103 women with polycystic ovary syndrome and 96 age‐matched healthy controls. Serum VEGF‐B levels were determined in all participants, and 44 polycystic ovary syndrome patients randomly received metformin. Measurements We measured VEGF‐B levels in healthy controls and women with polycystic ovary syndrome before and after metformin treatment. Results Women with polycystic ovary syndrome had higher serum VEGF‐B levels, which decreased with metformin treatment. In the lean and overweight/obese groups, patients with polycystic ovary syndrome had higher plasma VEGF‐B levels than did healthy controls ( P < 0·05). VEGF‐B levels were correlated with body mass index, body fat percentage, M values, homeostasis model assessment of insulin resistance and β‐cell function indices. A multiple linear regression analysis showed that VEGF‐B level was associated with M values after adjusting for age, body mass index, serum sex hormones and serum lipids in women with polycystic ovary syndrome. Conclusions Serum VEGF‐B is significantly higher in women with polycystic ovary syndrome and is closely and positively related to insulin resistance. Metformin treatment reduces VEGF‐B levels and ameliorates insulin resistance.